LRRC3-DT

Across TCGA pan-cancer cohorts, LRRC3-DT RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of LRRC3-DT’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where LRRC3-DT RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LRRC3-DT is over-expressed in tumor, although a few such as BRCA and STAD show the opposite, repressed pattern.

KIRP, BRCA, and STAD are the cancer types where LRRC3-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LRRC3-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	All	+0.199	<.001	9	view →
BRCA	Female	All	−0.105	<.001	6	view →
STAD	All	All	−0.765	<.001	5	view →
CHOL	All	All	−0.571	<.001	3	view →
READ	All	All	−0.356	.011	2	view →
PRAD	All	All	+0.233	<.001	2	view →
THCA	Male	III,IV	−0.118	.008	2	view →
HNSC	Male	III,IV	+0.094	.035	2	view →
BLCA	Male	IV	−0.325	.026	1	view →
LIHC	Male	II,III,IV	−0.208	.026	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

LRRC3-DT–KIRP

Open the KIRP breakdown →